See What HealthDay Can Do For You
Contact Us

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

hospital bed

MONDAY, Dec. 11, 2017 (HealthDay News) -- For patients with advanced-stage Hodgkin's lymphoma, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) have superior efficacy to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), according to a study published online Dec. 10 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in Atlanta.

Joseph M. Connors, M.D., from the British Columbia Cancer Agency in Vancouver, Canada, and colleagues conducted a phase 3 trial involving patients with previously untreated stage III or IV classic Hodgkin's lymphoma. A total of 664 patients were assigned to receive A+AVD and 670 were assigned to receive ABVD.

The researchers found that the two-year progression-free survival rates were 82.1 and 77.2 percent in the A+AVD and ABVD groups at a median follow-up of 24.9 months (hazard ratio for an event of progression, death, or modified progression, 0.77; 95 percent confidence interval, 0.60 to 0.98; P = 0.03). There were 28 and 39 deaths with A+AVD and ABVD (hazard ratio for interim overall survival, 0.72; 95 percent confidence interval, 0.44 to 1.17; P = 0.19). There was a trend in favor of A+AVD for all secondary efficacy end points.

"A+AVD had superior efficacy to ABVD in the treatment of patients with advanced-stage Hodgkin's lymphoma, with a 4.9 percentage-point lower combined risk of progression, death, or noncomplete response and of subsequent anticancer therapy at two years," the authors write.

The study was funded by Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals, and Seattle Genetics.

Abstract
Full Text
Editorial
More Information

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.